Enavate Sciences Gp, LLC reported 8 holdings worth US$280M as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Enavate Sciences Gp, LLC reported 8 holdings worth US$280M as of Sep 30, 2026. Largest: Zenas BioPharma, Inc., Immunome, Inc. and Braveheart Bio, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 8
- Value as reported
- US$280M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Zenas BioPharma, Inc. | 2.92M | US$78.7M | 28.1% |
| Immunome, Inc. | 3.61M | US$77.7M | 27.8% |
| Braveheart Bio, Inc. | 3.67M | US$74.2M | 26.5% |
| Sionna Therapeutics, Inc. | 2.48M | US$13M | 4.7% |
| Upstream Bio, Inc. | 2.46M | US$13M | 4.6% |
| BridgeBio Oncology Therapeutics, Inc. | 2.63M | US$10.8M | 3.8% |
| Compass Therapeutics, Inc. | 7.79M | US$8.1M | 2.9% |
| CAMP4 Therapeutics Corporation | 1.04M | US$4.21M | 1.5% |
Source
Download original · View original at SEC